US judge lets Lilly keep running ads comparing Zepbound and Mounjaro with Wegovy and Ozempic
A New Jersey federal judge refused Novo Nordisk's request for a preliminary injunction against Eli Lilly's comparison ads, saying Novo hadn't shown irreparable harm. Novo's false-advertising lawsuit, which argues the ads compared against lower Wegovy and Ozempic doses, continues.
Source: Claims Journal (Bloomberg) (27 Oct 2026). Image: Claims Journal (Bloomberg).